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Abstract
Arenaviruses such as Lassa virus (LASV) cause significant morbidity and mortality in endemic areas.
Using a glycoprotein (GP) exchange strategy, we have recently developed live-attenuated arenavirus
vaccine prototypes (rLCMV/VSVG) based on lymphocytic choriomeningitis virus (LCMV), a close
relative of LASV. rLCMV/VSVG induced long-term CD81 T cell immunity against wild-type virus
challenge and exhibited a stably attenuated phenotype in vivo. Here we elucidated the innate and
adaptive immune requirements for the control of rLCMV/VSVG. Infection of RAG2/2 mice resulted in
persisting viral RNA in blood but not in overt viremia. The latter was only found in mice lacking both
RAG and IFN type I receptor. Conversely, absence of IFN type II signaling or NK cells on an RAG-
deficient background had only minor effects on vaccine virus load or none at all. rLCMV/VSVG
infection of wild-type mice induced less type I IFN than did wild-type LCMV, and type I as well as
type II IFNs were dispensable for the induction of virus-specific memory CD8 T cells and virus-
neutralizing antibodies by rLCMV/VSVG. In conclusion, the adaptive immune systems are essential
for elimination of rLCMV/VSVG, and type I but not type II IFN plays a major contributive role in
lowering rLCMV/VSVG loads in vivo, attesting to the attenuation profile of the vaccine. Nevertheless,
IFNs are not required for the induction of potent vaccine responses. These results provide a better
understanding of the immunobiology of rLCMV/VSVG and will contribute to the further development
of GP exchange vaccines for combating arenaviral hemorrhagic fevers.
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Introduction
Smallpox has been eradicated by vaccination and similar
attempts for poliovirus hold promise, while the fight against
other viral pathogens is far less advanced and remains an
urgent biomedical challenge (1). The Old World arenavirus
Lassa virus (LASV) can cause hemorrhagic fever in humans
and falls into the latter category of pathogens. In the en-
demic areas of West Africa, it causes an estimated number
of 300 000 clinically manifest infections each year, leading
to a few thousand deaths (2). Furthermore, LASV and other
hemorrhagic arenaviruses are a concern owing to their po-
tential misuse in biological warfare (3). Still, the available
options for treatment are unsatisfactory and—with the
exception of Junin virus (4)—vaccines remain unavailable
for clinical use. Several strategies are being pursued for
creating an LASV vaccine, including DNA vaccination and
bacterial as well as viral vectors. However, live-attenuated
vaccines are often the most efficient in providing protection
against infection particularly when aiming for long-term im-
munity (5–7). Mopeia virus—a close relative of LASV—as
well as reassortant viruses containing Mopeia and LASV
gene segments have therefore been considered as LASV
vaccine candidates (8–12). Still, there remains a need for
vaccine candidates with an optimal efficacy and safety pro-
file. By exploiting the reverse genetic system for lymphocytic
choriomeningitis virus (LCMV) (13, 14), we have recently
shown that live-attenuated arenavirus vaccine prototypes can
be generated by exchange of their glycoprotein (GP) for the
unrelated GP of vesicular stomatitis virus (VSV) (15), a rhab-
dovirus. The resulting vaccine prototypes (rLCMV/VSVG)
were attenuated in cell culture and in mice; yet, they were still
able to induce vigorous CD8 T cell responses against virus
internal proteins and to confer long-term protection against
wild-type LCMV challenge (15). In addition, potent antibody
responses to the foreign VSVG envelope protein were elicited
and protected against lethal VSV challenge (16).
We have previously demonstrated that rLCMV/VSVG has
lost the pathogenic potential of wild-type LCMV (15–17).
However, this vaccine prototype is replication competent and
has hence raised a number of questions related to its poten-
tial future use in immunocompromized patients. Accordingly,
the high prevalence of HIV in LASV endemic areas has been
a major impediment to the introduction of recombinant vac-
cinia virus-based LASV vaccines. It was therefore of interest
to analyze mechanisms of rLCMV/VSVG immune control
in vivo and to investigate immune responses in animal mod-
els of immunodeficiency. Here we have dissected the role of
individual innate and adaptive immune pathways in rLCMV/
VSVG control and elimination. For this purpose, we exploited
a range of gene-targeted mouse models (described in
Table 1) that lack type I and type II IFN signaling, T and B
cells (owing to deficiency in recombination activation gene
1) and NK cells in various combinations. Since the role of in-
nate immunity in facilitating vaccination has become increas-
ingly appreciated, we have aimed to characterize the
dependence of rLCMV/VSVG-induced vaccine responses on
IFN signaling, since the role (18–21).
In this study, we found that adaptive immunity is key for
eliminating our live-attenuated arenavirus vaccine prototype.
Furthermore, type I IFN contributed substantially to keep the
infection in check, in a manner independent of T and B cells,
thereby determining systemic vaccine virus loads in animals
lacking adaptive immunity. This study also revealed that
rLCMV/VSVG induced less type I IFN than wild-type LCMV
(LCMV-ARM) and that type I and II IFNs are both dispens-
able for the induction of potent vaccine-induced cellular and
humoral immune responses.
Methods
Mice and animal experiments
IFNa/bR/ IFNcR/ (22), RAG/ (23), RAG/ cc/ (24),
RAG/ IFNa/bR/ (25), RAG/ IFNcR/ (25) and RAG/
IFNa/bR/ IFNcR/ (25) (see also Table 1) and C57BL/6 as
well as 129Sv/Ev wild-type control mice were bred and housed
under SPF conditions at the Institute of Laboratory Animal
Science, University of Zurich. Animal experiments were carried
out with authorization of the Veterina¨ramt of the Kanton Zu¨rich
and in accordance with the Swiss law for animal protection.
Virus strains, immunofocus assay and infection protocol
LCMVARM5.3b (LCMV-ARM) is a triple plaque-purified isolate
of ARM CA 1371 originally obtained from M. J. Buchmeier
(The Scripps Research Institute, La Jolla, CA). rLCMV/INDG
and rLCMV/NJG were generated by reverse genetic techni-
ques in which the LCMV GP ORF was substituted with either
the ORF of VSV G serotype Indiana (IND) or serotype New
Jersey (NJ) (compare Supplementary Figure 1A, available at
International Immunology Online, and 15, 17). The two
recombinant viruses as a common entity are also referred to
as ‘rLCMV/VSVG’. All viruses were grown on BHK-21 cells
and viral infectivity was titrated in a standard immunofocus
assay on MC57G cells (27). The mice were infected intrave-
nously at a standard dose of ;2 3 105 PFU unless stated
differently.
IFNa ELISA
Concentration of mouse IFNa in 1:10 with PBS prediluted
sera was measured by ELISA according to the manufac-
turer’s suggestions (PBL Interferon Source, Piscataway, NJ,
USA).
Virus-specific CD8+ T cell quantification and VSV
neutralization assay
CD8+ T cell responses were measured by flow cytometry
using H2-Db tetramers loaded with the LCMV-derived peptide
epitope NP396–404 combined with antibodies specific to the
surface markers CD8 and B220/CD45R (BD Pharmingen,
Table 1. Gene-deficient mouse models used in this study
Knockout mouse strain description Backgrounda T cells B cells NK cells IFNa/b R IFNc R References
IFNa/bR/ IFNcR/ 129Sv/Ev + + (+)b   (22)
RAG/ C57BL/6   + + + (23)
RAG/ cc/ C57BL/6    + + (24)
RAG/ IFNa/bR/ 129Sv/Ev/C57BL/6 mixed   (+)b  + (25)
RAG/ IFNcR/ 129Sv/Ev/C57BL/6 mixed   (+)b +  (25)
RAG/ IFNa/bR/ IFNcR/ 129Sv/Ev/C57BL/6 mixed   (+)b   (25)
a129Sv/Ev and C57BL/6 mice are equally resistant to both, wild-type LCMV (26) and rLCMV/VSVG (data not shown), justifying the comparative
analysis of the different knockout strains on C57BL/6 and C57BL/6 x 129Sv/Ev mixed backgrounds.
bMice deficient in IFN I receptor, IFN II receptor or both have been reported to have immature NK cells with severely impaired cytotoxic activity
(30–32).
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Allschwil, Switzerland) (15). The frequencies shown represent
the percentage of tetramer-positive cells within CD8+ B220
peripheral blood lymphocytes. VSV-neutralizing antibody titers
were determined in a plaque reduction assay on Vero cells as
previously described (16).
RNA isolation and quantitative reverse transcription–PCR for
the detection of LCMV nucleoprotein
Viral RNA was isolated from mouse serum using the QIAamp
Viral RNA Mini kit (Qiagen, Hombrechtikon, Switzerland). The
following oligonucleotides specific to the nucleoprotein (NP)
gene of LCMV strain ARM were designed with the software
Primer Express version 1.5 (Applied Biosystems, Rotkreuz,
Switzerland) to generate a 75-nt-long amplicon: forward pri-
mer NP1992f: 5#-ACTGACGAGGTCAACCCGG-3#, reverse
primer NP2057r: 5#-CAAGTACTCACACGGCATGGA-3# and
TaqMan probe: NP2035: 5#-FAM-CTTGCCGACCTCTTCAAT-
GCGCAA-BHQ1-3#. Assay oligonucleotides and details have
been deposited in the public database RTPrimerDB with ID
number 7815.
For absolute quantification of LCMV RNA copies, a
401-nt-long PCR product was amplified using the primers
NP2206r-T7overhang 5#-gaaattaatacgactcactataggGAG-
GAATTGACCCCAACGCT-3# (small letters indicate T7
promoter and upstream sequence) and NP1808f 5#-TCCA-
zGTATGCATCTTACACAACCAG-3# on a plasmid template
containing the NP ORF of LCMV-ARM. The amplicon was
gel purified with the QIAquick Gel Extraction kit (Qiagen)
and subsequently used to generate RNA standards by T7 in
vitro transcription. After DNase digestion with the Turbo
DNA-free kit (Ambion, Rotkreuz, Switzerland), in vitro
transcripts were quantified by RNA 6000 Nano RNA Chip
on a 2100 Bioanalyzer (Agilent Technologies, Basel,
Switzerland) to calculate the number of RNA copies. This
synthetic RNA was serially 10-fold diluted with DEPC-treated
H2O containing 100 ng ll
1 yeast tRNA carrier (Ambion) in
DNA LoBind tubes (Eppendorf, Scho¨nenbuch, Switzerland)
and used for standardization of the TaqMan assay. The follow-
ing one-step quantitative reverse transcription–PCR (qRT-
PCR) protocol was run using the TaqMan One-Step RT-PCR
Master Mix (Applied Biosystems) and primers/probe at
a concentration of 300 nM/250 nM: 30 min at 48C; 10 min
at 95C; 45 cycles of 15 s at 95C and 1 min at 56C. Small
amounts of an internal positive control were used to control
for RNA extraction efficiency and downstream processing.
This in vitro RNA transcript with binding sites for NP1992f
and NP2057r but with a different probe-binding area was
spiked into each collected serum sample prior to RNA isola-
tion and was simultaneously quantified with a second probe
labeled with a different fluorescent dye (5#-JOE-AAAGGC-
CAAGAAGGGCGGAAAGTCC-BHQ1-3#). All samples were
run in duplicates on 7700SDS or 7900HTS machines
(Applied Biosystems) and analyzed with the SDS1.9 or
SDS2.0 software (Applied Biosystems).
Statistical analysis
One-way analysis of variance was used for the comparison of
multiple groups, and t-tests (unpaired, two tailed; with
Bonferroni correction for multiple comparisons) assessed differ-
ences between two groups (GraphPad Prism software 4.0a).
Viral titers were log transformed for analysis. P-values >0.05
were considered not statistically significant, P < 0.05 was con-
sidered significant (*) and P < 0.01 as highly significant (**).
Results
Contribution of innate and adaptive immune responses to
rLCMV/INDG control
First, we investigated the role of adaptive immunity in con-
trolling rLCMV/VSVG. RAG/ mice lack T and B cells and
are known to develop lifelong overt viremia when infected
with LCMV (LCMV-ARM, Fig. 1A) (28). In contrast, rLCMV/
INDG or rLCMV/NJG infection failed to cause overt viremia
(Fig. 1A). Still, viral RNA persisted in the blood of these
animals (a status referred to as ‘RNemia’) but was only de-
tectable when assessed with a highly sensitive qRT-PCR
assay (Fig. 1B, Supplementary Figure 1 is available at
International Immunology Online). These observations in
RAG/ mice indicated that adaptive immunity was neces-
sary to eliminate rLCMV/VSVG, but they suggested also
that innate immune pathways suppressed replication of
this vaccine virus to fairly low levels.
IFNs play a key role in the control of many viruses includ-
ing wild-type LCMV (22, 29). Thus, we hypothesized that
IFNs might be at the root of strongly suppressed rLCMV/
VSVG replication in RAG/ mice, and we tested vaccine
virus control in IFNa/bR/ IFNcR/ double-deficient ani-
mals. These mice are unable to control wild-type LCMV
(22, 29) but they rapidly eliminated rLCMV/VSVG from
blood (Fig. 1C and D). Two different explanations could have
accounted for these results: (i) either IFN type I and II signal-
ing was not involved in rLCMV/VSVG control or (ii) adaptive
immune defense and IFNs exhibited considerable redun-
dancy in controlling the vaccine virus. To discriminate be-
tween these possibilities, we analyzed rLCMV/VSVG control
in mice lacking RAG as well as the IFN type I receptor
(RAG/ IFNa/bR/) or additionally lacking the IFN type II
IFN receptor (RAG/ IFNa/bR/ IFNcR/). Both geno-
types of mice developed overt viremia, which was also
reflected in RNemia levels exceeding those of RAG/ mice.
This suggested that IFN type I signaling potently contained
rLCMV/VSVG infection. Thus, IFN type I signaling determined
largely the level of viral persistence in the absence of adap-
tive immunity. In addition, small but reproducible differences
in virus loads between RAG/ IFNa/bR/ and RAG/ IFNa/
bR/ IFNcR/ mice (P < 0.01) pointed toward a minor con-
tributive role of IFN type II signaling in vaccine virus control.
Conversely, we could not detect a clear contribution of NK
cells in controlling rLCMV/VSVG when testing its replication
in RAG/ mice additionally lacking the common c chain of
the IL receptors (RAG/ cc/). RAG/ cc/ mice are NK
cell deficient but did not exhibit viremia and RNemia was in
similar ranges as in RAG/ mice. In line with this observa-
tion, combined IFN type I and type II receptor deficiency
also results in impaired NK cell activity (30–32) but did not
prevent efficient control of rLCMV/VSVG in IFNa/bR/
IFNcR/ mice (Fig. 1C and D).
Of note, neither the overt viremia in RAG/ IFNa/bR/
and RAG/ IFNa/bR/ IFNcR/ mice nor low-level RNemia
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in the other RAG-deficient mouse strains was associated
with manifestations of disease. This confirms our earlier
observations on the apathogenic behavior of rLCMV/VSVG
(15, 17, 33) and extends these findings to hosts with severe
and combined immune deficiencies.
‘RNemic’ serum of RAG/ cc/ and RAG/ IFNcR/ mice
can transfer infection to RAG/ IFNa/bR/ IFNcR/
indicator mice
Persisting rLCMV/INDG in RAG/, RAG/ cc/ and
RAG/ IFNcR/ mice could only be detected by qRT-PCR
(Fig. 1). To test for residual infectivity, we transferred serum
from rLCMV/INDG-infected RAG/ cc/ and RAG/
IFNcR/ mice into highly susceptible RAG/ IFNa/bR/
IFNcR/ mice. This in vivo bioassay (schematically
depicted in Fig. 2A) revealed residual low-level infectivity in
the sera of six out of seven individual RAG/ cc/ and
RAG/ IFNcR/ mice, resulting in overt viremia of recipient
RAG/ IFNa/bR/ IFNcR/ mice 30 days after serum
transfer (Fig. 2B). Serum of viremic rLCMV/INDG-infected
RAG/ IFNa/bR/ mice was also infectious as expected
based on our immunofocus assay data (compare with
Fig. 1C). In contrast, serum from IFNa/bR/ IFNcR/ mice
(free of detectable viral RNA) served as a negative control
and failed to transfer infection to RAG/ IFNa/bR/
IFNcR/ mice, confirming that type I and II IFNs were
dispensable for eliminating rLCMV/INDG infection in an
RAG-competent background. This shows that rLCMV/INDG-
infected RAG/, RAG/ cc/ and RAG/ IFNcR/ mice
still harbored low levels of infectious virus, which was,
however, below the detection level of the conventional
immunofocus assay.
rLCMV/INDG elicits unimpaired CD8 T cell and antibody
responses in IFNa/bR/ IFNcR/ mice
LCMV-ARM-induced T cell responses and antibody induction
by VSV are known to greatly depend on type I IFN signaling
(34–37). Nevertheless, elimination of rLCMV/VSVG in IFNa/
bR/ IFNcR/ mice was apparently the result of adaptive
immune responses and occurred independently of IFN type I
signaling. Moreover, rLCMV/INDG and rLCMV/NJG induced
significantly less serum IFNa than LCMV-ARM (Supplemen-
tary Figure 2 is available at International Immunology Online).
These findings, together with unimpaired vaccine virus control
Fig. 1. Differential requirement for innate and adaptive immune responses in controlling rLCMV/INDG. (A and B): RAG/ mice were infected
with LCMV-ARM, rLCMV/INDG or rLCMV/NJG. Viral infectivity in blood was determined by immunofocus assay (A) and viral RNA copies in serum
were quantified by qRT-PCR (B). (C and D): IFNa/bR/ IFNcR/, RAG/ cc/, RAG/ IFNa/bR/, RAG/ IFNcR/, RAG/ IFNa/bR/
IFNcR/ mice and wild-type mice were infected with rLCMV/IND and viral infectivity (C) and viral RNA copies (D) were determined by
immunofocus assay and qRT-PCR, respectively. Symbols represent the mean 6 standard error of the mean of four mice per group.
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in IFNa/bR/ IFNcR/ mice, raised the possibility that
rLCMV/VSVG-induced T cell and antibody responses
depended less on type I IFN than those induced by the
parent wild-type viruses. To directly address this possibility,
we studied the adaptive immune response to rLCMV/INDG in
IFNa/bR/ IFNcR/ mice. CD8+ T cells specific for the
immunodominant LCMV-NP-derived epitope NP396–404
(NP396) were monitored in peripheral blood (Fig. 3A). Unlike
reported from LCMV-ARM-infected IFN type I receptor-
deficient mice (34–37), we found an unimpaired virus-specific
CD8 T cell response in IFNa/bR/ IFNcR/ mice. It even
reached 5- to 10-fold higher frequencies than in wild-type
mice, and memory populations of specific CD8+ T cells per-
sisted throughout day 447 after immunization. To assess the
functionality of these memory CD8+ T cells, rLCMV/INDG im-
mune splenocytes from IFNa/bR/ IFNcR/ mice were
transferred to naive syngeneic wild-type mice that were sub-
sequently challenged with LCMV-ARM. After transfer, a small
population of NP396-specific CD8+ T cells was detected in
the recipient mice (;0.2% 1 week after transfer, data not
shown). Subsequent intracranial infection with LCMV-ARM
led to a rapid expansion of these transferred memory CD8+ T
cells (Fig. 3B) and protected the recipients against lethal
LCMV-induced choriomeningitis (n = 3, data not shown).
Of note, protection in this challenge setting relies entirely
on memory CD8 T cells (38), whereas B cell memory cannot
contribute to protection owing to the different surface GPs
of rLCMV/INDG (immunization) and LCMV-ARM (chal-
lenge). Hence, these results attested to the functionality of
rLCMV/VSVG-induced memory CD8+ T cells in IFNa/bR/
IFNcR/ mice. In analogy to CD8+ T cell responses,
rLCMV/INDG-specific neutralizing antibody responses in
IFNa/bR/ IFNcR/ mice reached significantly higher
peak titers than in wild-type mice and subsequently
remained in the wild-type range for >6 months (Fig. 3C).
These results indicated that neither IFN type I nor IFN type
II signaling were necessary for potent CD8 T cell responses
and neutralizing antibody induction by rLCMV/VSVG and
that memory formation was similarly unimpaired in the ab-
sence of these pathways.
Discussion
Vaccine design aims to provide optimal immunogenicity and
protective capacity in combination with a reliable safety pro-
file (39). Reverse genetic engineering allows the targeted at-
tenuation of viruses as well as the directed enhancement of
immunogenicity and incorporation of desirable immunomod-
ulatory properties (1, 40). Here we found that rLCMV/VSVG,
the first live-attenuated arenavirus vaccine prototype engi-
neered by reverse genetic techniques, was largely con-
trolled by type I IFN signaling but its elimination depended
on adaptive immune responses. Accordingly, IFN type I sig-
naling reduced viral replication in RAG/, RAG/ cc/
and RAG/ IFNcR/ mice to below the detection limit of
the immunofocus assay, whereas the combined deficiency
in RAG and IFN type I receptor (i.e. RAG/ IFNa/bR/ and
RAG/ IFNa/bR/ IFNcR/ mice) permitted viral replication
at a level that was detectable as overt viremia. In addition,
IFN type II had a moderate effect on rLCMV/VSVG replication
when tested in the context of an IFN type I and RAG double
deficiency (compare RAG/ IFNa/bR/ versus RAG/
IFNa/bR/ IFNcR/ mice in Fig. 3C and D).
We acknowledge that RAG-deficient mice exhibit a disrup-
ted splenic microarchitecture with an incompletely devel-
oped marginal zone, a compartment which has been shown
to contribute to type I IFN responses in LCMV infection (41).
Thus, we cannot formally exclude the possibility that impaired
IFN type I responses to rLCMV/VSVG in RAG-deficient ani-
mals may negatively affect innate immune control and thereby
may further reduce these animals’ ability to eliminate the vac-
cine virus. On the other hand, substantially different virus
loads in RAG and RAG/ IFNa/bR/ mice demonstrate that
the IFN type system is fairly capable to contain rLCMV/VSVG
even in RAG-deficient mice. Thus, the efficiency of the type I
IFN system in reducing rLCMV/VSVG replication may be
Fig. 2. Transfer of RNemic serum from aviremic mice is infectious for RAG/ IFNa/bR/ IFNcR/ mice. (A): Schematic description of the
experimental setup. Sera were collected from individual RAG/ cc/, RAG/ IFNa/bR/, IFNa/bR/ IFNcR/ and RAG/ IFNcR/ mice
infected 49 days previously with rLCMV/INDG and were transferred into individual RAG/ IFNa/bR/ IFNcR/ indicator mice. Thirty days after
serum transfer, viral infectivity in the blood of the recipient RAG/ IFNa/bR/ IFNcR/ mice was measured by immunofocus assay (B). Viral
titers of individual recipient indicator mice are shown.
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underestimated, rather than overestimated, further supporting
our conclusions that IFN type I is a main pathway of rLCMV/
VSVG control in vivo. Lower IFN type I responses in wild-type
mice to rLCMV/VSVG than to LCMV-ARM further highlight that
IFN-mediated efficient containment of rLCMV/VSVG as com-
pared with wild-type LCMV is not due to a differential IFN in-
duction. Instead, it appears that the two viruses respond
differentially to IFN type I and/or that the intrinsically different
replicative potential combined with slower spread of rLCMV/
VSVG (15–17) renders IFN type I more efficient.
rLCMV/VSVG elicited even higher frequencies of virus-
specific CD8 T cells and stronger neutralizing antibody
responses when inoculated into mice lacking IFN type I and
II signaling. This unexpected finding contrasted with the
documented type I IFN dependence of CD8 T cell responses
to LCMV-ARM infection (34–37) and is likely due to higher
viral antigen load. This is illustrated by the detection of 40-
fold higher levels of rLCMV/INDG RNA levels on day 4 in
IFNa/bR/ IFNcR/ compared with wild-type mice
(Fig. 1D). However, further investigations are needed to dis-
sect the underlying molecular mechanisms and examine al-
ternative pathways such as IL-12 signaling—known to be
suppressed by type I IFN during LCMV-ARM infection—
which may bypass the type I IFN dependence of adaptive
immune responses (42).
The discrepancy between considerable levels of RNemia
and undetectable serum infectivity matches analogous find-
ings in cell culture-grown virus preparations. rLCMV/INDG
virus stocks consistently exhibited 10- to 100-fold higher
viral RNA to PFU ratios than LCMV-ARM (data not shown).
This difference can most likely be attributed to the lack of
functional interactions between VSVG and the LCMV ribonu-
cleoprotein (43). Incorporation of the foreign VSVG envelope
protein into budding rLCMV/VSVG virions is presumably less
efficient than for the GP of LCMV, representing one likely
mechanism for rLCMV/VSVG attenuation (15). A molecular
interplay between the LCMV-GP cytoplasmic domain, NP
and the Z protein is involved in recruitment of the GP into
budding LCMV virions, whereas particle formation occurs in-
dependently of GP and is driven by the Z protein (44). The
10- to 100-fold reduction in rLCMV/VSVG particle infectivity
therefore seems to be a logical consequence of GP ex-
change, and the predominant production of non-infectious
viral particles may explain why rLCMV/VSVG propagates
more slowly than LCMV-ARM, both in cell culture and in
infected mice (15–17). It remains currently unknown whether
the differential dependence of the adaptive immune re-
sponse on type I IFN to LCMV-ARM and rLCMV/VSVG is
merely a consequence of slower replication of the latter virus
or whether other factors such as altered host cell interfer-
ence, differential cellular tropism and possibly yet other
alterations of virus–host interactions contribute to this
phenomenon in ways that may not necessarily be mutually
exclusive.
The characteristics described here provide additional ra-
tionale (15) to test the safety and immunogenicity of enve-
lope exchange-based arenavirus vaccines in non-human
primates and eventually humans. To ensure potent cellular
immune responses, the foreign envelope protein should
mediate efficient entry of vaccine virus particles into human
host cells, allowing for in vivo gene expression. In this re-
spect, VSVG is a first-choice candidate since it is pantropic
and efficiently fuses to all known human cell types, which
also explains its wide use in gene therapy approaches (45).
To assure sufficient gene expression, the vaccine virus
should have the ability to replicate in human cells. Wild-type
LCMV can cause severe disease in immunosuppressed
transplant recipients (46) owing to unchecked viral replica-
tion. This suggests that a species barrier seems unlikely to
prevent immunogenicity in humans while simultaneously em-
phasizing the need for stable attenuation.
Recently, we have also developed a replication-deficient
vector systems based on LCMV (47), a platform aimed at
inducing immunity to unrelated infectious agents or tumors.
Fig. 3. Vigorous CD8+ Tcell and antibody responses in rLCMV/INDG-
infected IFNa/bR/ IFNcR/ mice. (A) IFNa/bR/ IFNcR/ and
wild-type mice were infected intravenously with LCMV/INDG. H2-Db-
restricted NP396-specific CD8+ T cells (A and B) in peripheral blood
were enumerated by FACS. (B) 107 splenocytes of IFNa/bR/
IFNcR/ mice immunized 447 days previously with rLCMV/INDG
were transferred into syngeneic recipient wild-type mice. NP396-
specific CD8+ T cells were measured 5 days after intracranial
challenge with LCMV-ARM. (C) VSV-neutralizing serum antibody
titers were assessed on the indicated time points. Symbols and bars
represent the mean6 standard error of the mean of three to four mice
per group.
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In contrast, live-attenuated envelope exchange viruses are
designed to induce cellular immunity to the homologous
virus or to closely related arenaviruses. Replication compe-
tence of envelope exchange vaccines obviates the use of
genetically engineered cell lines in the production process
(47) and thus may represent an important practical advan-
tage over replication-deficient vectors, both in terms of the
ease of production and in production yields. Furthermore,
replicating vaccine viruses may serve as potent booster for-
mulations for arenavirus-specific immunity upon primary im-
munization with a replication-deficient vector. Thus, both
approaches are complementary, and they each have their
specific advantages and preferential areas of application.
In summary, this study has dissected the contributions of
the individual arms of the adaptive and innate immune sys-
tem to control of rLCMV/VSVG vaccine prototypes in vivo.
Of particular relevance for future application in combating
arenaviral hemorrhagic fevers, we have not observed clini-
cally manifest disease when administering the vaccine to
several mouse strains with severe and combined immunode-
ficiencies. Further, we found that rLCMV/VSVG induces po-
tent and long-lasting memory T and B cell responses in the
absence of IFN signaling, underscoring the excellent immu-
nogenicity of this vaccine prototype even under conditions
of partial immunodeficiency. These insights into the immu-
nobiology of rLCMV/VSVG provide additional justification to
further pursue GP exchange as a molecular strategy to engi-
neer live-attenuated arenavirus vaccines, with the goal of in-
ducing T cell-mediated immunity against LASV and related
hemorrhagic fever viruses.
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Supplementary data are available at International Immunol-
ogy Online.
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